BioWorld MedTech

March 2, 2016

Nexstim facing uncertain future after stroke rehabilitation device trial fails

Nexstim Plc faces an uncertain future with its Navigated Brain Therapy (NBT) for stroke rehabilitation after a phase III study of the device failed to meet its primary endpoint. Read More

In releasing list of outstanding devices, China is promoting its med-tech sector

FDA posts September 2015 warning letter to Rewalk for 522 study

Savara so good: Aerovanc inhaled vancomycin nears pivotal with $20M series C

FDA decisions on Neuro-Spinal Scaffold propel Invivo's INSPIRE study, stock forward

Financings

Appointments & advancements

Daily M&A

Other news to note

Product briefs

Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Photo of scale with woman sitting on floor holding head and arms on knees

Rethinking anorexia: A disorder of mind and metabolism

BioWorld Science

Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...